Liminatus Pharma (LIMN) Stock Forecast: StockMap's 2-Week Call
LIMN stock forecast: StockMap's model calls Liminatus Pharma Strong Underperform for the two weeks after the Nov 13 close: it expects LIMN to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on LIMN since Aug 21; by chance, a call on the same dates was right 62% of the time.
Liminatus Pharma last closed at $2.99, +7.94% on the session.
Against the IVW growth benchmark the position is +8.85% over the forecast window.
Liminatus Pharma's market cap is $4.02M as of November 13, 2026.
Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -69 (behind).
Where LIMN sits: sized by market cap, coloured by the day's move.
The read is built from 12 underlying insights — 1 bullish and 11 bearish.
Agreement across those insights is 92%.
45 daily calls for LIMN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Liminatus Pharma in the 98th percentile on return on equity, where 100 is best.
Liminatus Pharma is classified under Health Care / Biotechnology.
StockMap tracks Liminatus Pharma as the 376th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Liminatus Pharma ranks 384th of 391 in the group, against a group median of -0.24.